Psoriatic Arthritis Therapeutics Market Companies Analysis, Advancement and Precise Outlook – 2026

Transparency Market Research (TMR) has published a new report titled, “Psoriatic Arthritis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017. It is projected to expand at a CAGR of 11.4% from 2018 to 2026. High prevalence of psoriatic arthritis, large unmet medical needs, and new product approvals are anticipated to drive the global market in the next few years. North America is expected to dominate the global psoriatic arthritis therapeutics market during the forecast period, followed by Europe. Potential unmet medical needs for moderate to severe psoriatic arthritis, increase in adoption of biologic drugs, and approvals of new therapeutic drug classes in the U.S. and Europe are likely to drive the psoriatic arthritis therapeutics market in these regions during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period. 

psoriatic arthritis therapeutics market

High prevalence and increase in incidence rate of psoriatic arthritis to drive market

High prevalence and rise in incidence rate of psoriatic arthritis across the globe is a key factor driving the global psoriatic arthritis therapeutics market. Chances of developing psoriatic arthritis among patients with psoriasis is high, and the number of patients with psoriatic arthritis has been increasing significantly in the last few years. According to the International Federation of Psoriasis Association, more than 125 million people were affected with psoriasis, globally, in 2015. It is estimated that between 10% and 30% of patients with psoriasis tend to develop psoriatic arthritis. According to the study published in the Journal of the American Academy of Dermatology, in 2013, Denmark had the highest prevalence rate of psoriatic arthritis, with around 42% prevalence rate, while the lowest prevalence rates were recorded in Canada and Belgium. Thus, the high prevalence and substantial rise in incidence rate of psoriasis and psoriasis-led psoriatic arthritis across globe is a key factor driving the global psoriatic arthritis therapeutics market. 

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61917

Interleukin inhibitors and PDE4 inhibitors drugs to propel the psoriatic arthritis therapeutics market

The report offers a detailed segmentation of the global psoriatic arthritis therapeutics market based on different therapeutic drug classes approved and commercialized for psoriatic arthritis. Based on drug class, the global market has been segmented into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Interleukin inhibitors drugs have evolved as new therapeutic drug class for the treatment of psoriatic arthritis when other therapeutic drugs classes, especially TNF alpha inhibitors, fail to relieve the symptoms of psoriatic arthritis. Interleukin inhibitor drugs, especially IL-17A inhibitor drugs, have shown the highest clinical efficacy, as compared to any other biologic drug available, to relive the symptoms of psoriatic arthritis. Interleukin inhibitors have been recently approved for the treatment of psoriatic arthritis and are increasingly gaining popularity among physicians across the globe. Currently, only four interleukin inhibitors ? Cosentyx (Secukinumab), Stelara (USTEKINUMAB), Tremfya (Guselkumab) and Taltz (Ixekizumab) ? have been approved for the treatment of psoriatic arthritis. Interleukin inhibitors drug sales are estimated to rise about four times by the end of 2026. PDE4 inhibitor is the new therapeutic drug that was approved by the USFDA, in March 2014, for the treatment of psoriatic arthritis. Currently, Otezla (Apremilast) is the only approved PDE4 inhibitor drug for psoriatic arthritis treatment. Within one year of launch, Otezla generated a sale of more than US$ 1 Billion in the year 2016. 

Parenteral route of administration to dominate global market

In terms of route of administration, the global psoriatic arthritis therapeutics market has been segmented into oral route, parenteral route, and topical routes. The parenteral route segment dominated the global market in 2017. It is likely to maintain its dominance by the end of 2026. Majority of the therapeutic drugs available for the treatment of moderate to severe psoriatic arthritis are biologics drugs that are administered through the subcutaneous and intravenous routes. The high cost and large volume prescription of biologic drugs contributed to the leading share held by the parenteral route segment in 2017.

Hospital pharmacies segment to account for high market share

In terms of distribution channel, the global psoriatic arthritis therapeutics market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a significant share of the market by 2026. Rise in the number of hospital admissions of patients with psoriatic arthritis and high cost of treatment are anticipated to contribute to the high share of the segment by the end of 2026. Promising biologic product pipeline of leading biopharmaceutical companies is likely to receive approval and commercialization in the near future. Biologic drugs are most commonly and easily available at hospital pharmacy stores. Hence, expected launch and commercialization of biologic therapeutic drugs is likely to drive the hospital pharmacies segment during the forecast period. 

Asia Pacific offers high incremental opportunity

The psoriatic arthritis therapeutics market in Asia Pacific is projected to expand at a high CAGR during the forecast period. High prevalence of psoriatic arthritis in highly populated countries, such as China and India, rapidly improvement in health care infrastructure, increase in access to health care facilities, and rise in per capita health care expenditure in the region are likely to fuel the market in Asia Pacific during the forecast period. Large base of pharmaceutical companies in countries such as India, Japan, and China also drives the market in the region. High demand and increased adoption of biologic drugs in developed markets, such as Australia & New Zealand, are projected to propel the psoriatic arthritis therapeutics market in Asia Pacific. For instance, in Australia, the number of patients with severe psoriasis receiving treatment under the Pharmaceutical Benefit Scheme (PBS) with biologics has increased by more than 60% between 2014 and 2016. 

Get an Idea about the Offerings of Our Market Research Report from this Brochure : https://www.prnewswire.co.uk/news-releases/increasing-awareness-about-post-operative-care-and-changing-dynamics-of-healthcare-industry-to-present-lucrative-growth-opportunities-for-adhesion-barriers-market-finds-tmr-889098039.html

Key trend of M&A among leading players to diversify and strengthen psoriatic arthritis product portfolio

The global psoriatic arthritis therapeutics market is highly consolidated, with a few global players accounting for a major share in respective regions. Leading players in psoriatic arthritis therapeutics are engaged in mergers, acquisitions, and strategic collaborations to broaden their psoriatic arthritis therapeutics portfolio. For instance, more than 20 mergers, acquisitions, and strategic collaborations have taken place between 2014 and 2018. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of psoriatic arthritis therapeutics products. Key players operating in the psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company. 

Parenteral Nutrition Market Share, Status and Prospect 2019 – 2027

Transparency Market Research (TMR) has published a new report titled, ‘Parenteral Nutrition Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global parenteral nutrition market was valued at around US$ 5.6 Bn in 2018 and is projected to grow at a CAGR of 4.6% from 2019 to 2027.

Overview

  • Parenteral nutrition is a method of feeding a person intravenously. It is primarily referred to patients who are malnourished or at risk of malnutrition and have a non-functioning gastrointestinal (GI) tract. Carbohydrates, vitamins, fats, and minerals such as calcium represent the constituents of parenteral nutrition.
  • Parenteral nutrition is indicated for patients who cannot intake adequate nutrition orally or enterally, or who have compromised GI track.
  • Administration of parenteral nutrition could become imperative in cases of gastrointestinal diseases, fatal burns, AIDS, and cancer.
  • Parenteral nutrition products include a range of macronutrients such as carbohydrates, amino acids and lipid emulsions, and micronutrients such as vitamins, trace elements, and minerals.
  • Rise in incidence and prevalence of chronic diseases across the world is the major factor to drive the global market.
  • North America dominated the global parenteral nutrition market in 2018 and anticipated to dominate during the forecast period. Growing U.S. FDA approvals for the parenteral nutrition is one of the major factors to drive the market in this region.

Rise in prevalence of chronic diseases to Drive Market

  • Higher incidence & prevalence of chronic diseases across the world is the major driver for the growth of global parenteral nutrition market.
  • For instance, according to WHO, 2,378,785 new cancer cases were seen in North America in 2018. Also as per Globocan 2018, 5-year prevalence for all type of cancer in Europe was found to be 12,132,287 which is second only after Asia Pacific region.
  • Moreover rising incidence of malnutrition is also fuelling the growth of global parenteral nutrition market. This malnutrition is mainly seen due to poor dietary habits in developed countries & high poverty rate in developing regions and parenteral nutrition is considered as an essential treatment therapy to provide adequate nutrition support to malnourished patents.
  • Development of novel parenteral nutrition drugs and rising R&D activities for pipeline products are some of the major factors attributed for the growth of global parenteral nutrition market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3611

Single dose amino acid solutions Segment to Dominate Market

  • Based on type, the global parenteral nutrition market has been segmented into carbohydrates, parenteral lipid emulsions, single dose amino acid solutions, trace elements, electrolytes, & minerals, and vitamins
  • Single dose amino acid solutions is accounted for major market share in 2018 and is expected to dominate throughout the forecast period.
  • Single dose amino acid solutions segment is growing with a significant CAGR during the forecast period owing to abundant availability of these products and new unique amino acid-based parenteral formulation by major companies.

North America to Dominate Global Market

  • In terms of region, the global parenteral nutrition market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • North America accounted for major share of the global parenteral nutrition market in 2018 due to higher prevalence of chronic diseases, growing U.S. FDA approval for novel parenteral nutrition compounds, and higher research & development funding for new product development.
  • For instance, the American Heart Association estimated that 121.5 million adults in the U.S. had cardiovascular diseases between 2013 and 2016.
  • The parenteral nutrition market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. This can be ascribed to growing aging population which is more prone to chronic disease, rising awareness for parenteral nutrition, and improving healthcare infrastructure in the region.

Competitive Landscape

  • The global parenteral nutrition market is consolidated as few players hold majo0r market share in global market. Key players include Allergan plc., Pfizer Inc., B.Braun Melsungen AG, Fresenius Kabi AG, Grifols, S.A., Baxter International, Inc., Vifor Pharma Management Ltd.,and Sichuan Kelun Pharmaceutical Co., Ltd., among others

Get an Idea abot the Offerings of Our Market Research Report from this Brochure : http://www.prnewswire.com/news-releases/exploring-avenues-in-personalized-medical-care-defines-advances-in-red-biotechnology-market-valuation-to-touch-massive-us512-bn-by-2027-finds-transparency-market-research-301026016.html

The global Parenteral Nutrition market has been segmented as follows:

Global Parenteral Nutrition Market, by Type

  • Carbohydrates
  • Parenteral Lipid Emulsions
  • Single Dose Amino Acid Solutions
  • Trace elements, Electrolytes, & Minerals
  • Vitamins

Global Parenteral Nutrition Market, by Region

  • North AmericaU.S.
  • Canada
  • EuropeGermany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific         China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin AmericaBrazil
  • Mexico
  • Rest of Latin America
  • Middle East & AfricaGCC Countries
  • South Africa
  • Rest of Middle East & Africa

Cardiovascular Drugs Market Opportunities : Key Trends, Challenges and Standardization to 2025

The demand within the global cardiovascular drugs market is expected to rise in the years to follow. The aforementioned projection is based on the rising incidence of heart diseases, strokes, and cardiac arrests. The field of cardiology has become the cynosure of the healthcare industry, and regional governments have made heavy investments in this sector. Furthermore, the sedentary lifestyles of the masses have made them laid back and sluggish. This trend has become the leading cause of cardiovascular diseases across the world. The quest of the medical fraternity to educate the masses about the importance of a balanced and healthy lifestyle is a key trend within the healthcare industry.

Focus on Critical Care to Stabilize Market Growth

It is of imperative value to administer the best form of treatment for patients suffering from cardiac diseases. The heart is the most critical body organ, and research related to the heart’s functionality has always held an upper hand in medicine. Therefore, the global cardiovascular drugs market is set to attract a huge amount of revenues in the following years. The hereditary nature of several cardiac diseases has added to the worries of the medical professionals.

cardiovascular-drugs-market.jpg

However, availability of improved drugs and cardiac-care technologies have been a matter of relief for the global medical industry. Prescription of cardiovascular drugs is not expected to run out of practice due to their indispensability for heart patients. Furthermore, there are no invasive procedures or alternative medications that can substitute the use of cardiovascular drugs.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33281

Increasing Incidence of Cardiac Diseases

Lack of physical activity is considered as the leading cause of cardiovascular diseases. Furthermore, the eating habits of the people have changed abysmally, and this has affected the global healthcare index. Demand for junk food and oily cuisines is on a rise, and this is an adverse indicator for the healthcare industry. Considering the factors mentioned above, it is safe to expect that the global cardiovascular drugs market would expand a stellar pace in the years to follow.

Transparency Market Research (TMR), in a report on the global cardiovascular drugs market, finds that this market stood at a value of US$ 80 bn in 2016. This value is expected to rise in the following years. The CAGR of the cardiovascular drugs market for the period between 2017 and 2025 is tabulated at 1.0%. The sluggish rate of growth can be attributed to the reluctance of the masses toward consumption of excessive drugs.

The vendors operating in the global cardiovascular drugs market are projected to invest in online marketing. Market players such as Bayer AG, Pfizer, and Novartis are creating awareness campaigns around healthy food habits and exercise routines. These indirect forms of marketing are expected to play a key role in the growth of these market vendors.

The review is based on TMR’s report titled, “Cardiovascular Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025”.

Get an Idea about the Offerings of Our Market Research Report from this Brochure : https://www.prnewswire.com/news-releases/cholesterol-and-triglyceride-abnormalities-on-a-rise-driving-dyslipidemia-drugs-market-to-higher-trajectory-tmr-301024637.html 

The global cardiovascular drugs market is segmented by:

Drug Class

  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents
  • Others

Distribution Channel

  • Hospitals
  • Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East

Impressive Trends and Future Scope of Thyroid Gland Disorders Treatment Market Size

The global thyroid gland disorder treatment market represents a highly competitive and fragmented landscape. This is mainly due to the presence of numerous small and large players in the market, says Transparency Market Research. 

Some of prominent players operating in the global thyroid gland disorder marker are Abbott, Pfizer, GlaxoSmithKline, Mylan N.V., and Amgen. These players are relying on several strategies such as partnership agreements, regional expansions, brand awareness activities, and increase product profiliration in order to gain a competitive edge in the market. In addition, increasing FDA approval of novel drug patent for the treatment of thyroid gland disorder treatment market is expected to fuel rivalry among players in the coming years.

In june 2018, Hutchison China MediTech Limited, a key players in the global throid gland disorder treatment market has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine. Once developed and successfully tested the drug is expected to treat tumors and biliary tract cancer efficiently. This is expected to fuel tyroid gland disorder market in the coming years.

In the same year, another player called AmpliPhi Biosciences Corporation presented a AB-PA01 Bacteriophage Therap. As per the company it is helpful in treating patient with cystic fibrosis.

According to TMR, the global thyroid gland disorders treatment market was noted at a valuation of US$1,954.7 mn in 2016. The market is expected to rise at a steady 3.3% CAGR from 2017 to 2025. Rising at this CAGR, the global thyroid gland disorder treatment market is expected to hit a valuation of US$2,609.9 mn by 2025.

On the basis of geography, North America is anticipated to dominate the global thyroid gland disorder treatment market during the forecast period. This can be attributed by the fact higher investments in research and development of novel drugs and equipment for treatment of chronic disorders. Along with this, early adoption of advanced healthcare technologies, rising awareness and increasing geriatric populations are some of the predominant factors expected to drive the global thyroid gland disorder treatment market in the coming years. Based on disorder, the Hypothyroidism segment is expected to lead the global throid gland disorder treatment market in the forecast period.

global thyroid gland disorders treatment market

Side Effects of Thyroid Gland Disorder Treatment Drugs to Impede Growth

The global thyroid gland disorder treatment market is anticipated to garner a stready growth during the forecast period. Key factor contributing the growth of thyroid gland disorder treatment market include market include increasing prevalence of thyroid gland disorder, surge in geriatric people, rise in awareness programs by private and public body.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3113

However, side effects of thyroid gland disorder treatment drugs, habit forming nature and stringent government regulations regarding the sales of medicines are some of the factors expected to hamper growth in the global thyroid gland disorder treatment market. In addition to this asymptomatic nature of thyroid gland disorder is one factor impeding growth in the thyroid gland disorder treatment market. This is because several thyroid gland disorder cases left untreated owing to poor diagnostic.

Unprecedented Rise in Alcohol and Tobacco Consumptions to Drive Growth

Nevertheless, increasing cases of iodine deficiency across the globe is a strong factor expected to propel the growth in the global thyroid gland disorder treatment market.

Moreover, rise in alcohol and tobacco consumption also leads the thyroid disorders. This is because they contain thiocyanate, a compound responsible to degrade thyroid functioning. This is also expected to open several opportunities for growth of the global thyroid gland disorder treatment market.

This assessment of the global thyroid gland disorders treatment market is based on a recent market research report by Transparency Market Research, titled “Thyroid Gland Disorders Treatment Market (Disorders – Hypothyroidism (Levothyroxine and Liothyronine) and Hyperthyroidism (Imidazole and Propacil)) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017–2025.”

Get an Idea about the Offerings of Our Market Research Report from this Brochure : http://www.prnewswire.com/news-releases/animal-health-gains-prominence-as-role-shifts-from-pets-to-companions-contributing-to-growth-in-veterinary-radiography-system-market-notes-tmr-301022155.html

The global thyroid gland disorder treatment market has been segmented as follows:

  • DisordersHypothyroidismLevothyroxine
  • Liothyronine
  • HyperthyroidismImidazole
  • Propacil
  • GeographyNorth AmericaU.S.
  • Canada
  • EuropeGermany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia PacificChina
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin AmericaBrazil
  • Mexico
  • Rest of Latin America
  • Middle East and AfricaGCC Counties
  • South Africa
  • Israel
  • Rest of Middle East & Africa

Erythropoietin Drugs Market Trends : A Latest Research Report to Share Market Insights and Dynamics

The global erythropoietin drugs market is prognosticated to demonstrate steady growth in coming years, as reported by Transparency Market Research (TMR). The competitive ecosystem features a highly consolidated environment, with vendors involved in different tactics to beat the rival players. Leading vendors in the global erythropoietin drugs market engage in several organic and inorganic growth strategies. Mergers and acquisitions are a popular initiative undertaken by vendors in order to gain momentum in the global market. 

The improvement of distribution channels is expected to be focused on by vendors operating in the global erythropoietin drugs market. This is likely to encourage vendors to find more distributors in their supply chain system. This will further amplify competition among the market players. 

Research and development activities play a pivotal role in this industry, and market vendors are anticipated to engage in application-specific research. The segment of biosimilars is expected to offer rich growth opportunity to vendors, with increased number of clinical trials and approvals. Under-penetrated market will be the focus of established vendors and market entrants, with the aim of expansions/launches. 

Key vendors in the global erythropoietin drugs market are Johnson & Johnson, Amgen Inc., Biocon Ltd., F. Hoffmann-La Roche Ltd., and Pfizer, Inc. 

According to TMR’s predictions, the global erythropoietin drugs market is prognosticated to rise at a 7.5% CAGR over the forecast period from 2017 to 2025, and projected to be worth US$19.3 bn by the end of the forecast period. 

erythropoietin drugs market

Based on the geographical segmentation, the global erythropoietin drugs market is expected to be dominated by North America. The region boasts of fee waivers, favorable reimbursement policies, and approval associated with the product, propelling the North America market. On the basis of drugs class, Epotin alfa is anticipated to remain dominant over the forecast period. This could be attributed to the high prevalence of renal failures and cancer, as the drug is majorly used in these instances. 

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1856

Rising Incidence of Anemia to Drive Erythropoietin Drugs Market 

Substantial economic stresses are amplified by anemia and also affect the quality of life. AS reported by the Center for Disease Control and Prevention (CDC), some 5.5 million ambulatory care patients suffer from anemia due to a nutritional deficiency, while the second most prevalent cause is chronic disease. Although anemia is a common disease symptom, it remains undiagnosed and undertreated, particularly for patients with chronic renal diseases (CRD) that are not dialyzed. Approximately 20 million people in the U.S. have CKD, 2-4 million of which have anemia. Thus, an increasing number of anemia patients are driving the global market for erythropoietin. 

Introduction of Biosimilars to Emerge as Key Market Trend 

In the global erythropoietin drugs market, major pharmaceutical companies such as Pfizer, Amgen, and Novartis have shifted dramatically from reference drugs to biosimilars. Biosimilars are comparatively easy to develop and cost-effective, and need less time than biologics for approval. These associated benefits are anticipated in the forecast period to promote segment growth. 

Other factors contributing to his dominance include the presence of large patient populations and patent expiration of biologics. In addition, there has been an increase in the availability of some biosimilars in the market. Furthermore, the biosimilars segment is expected to gain traction with increased awareness and high spending on healthcare, opening up growth avenues in the global erythropoietin drugs market. 

New Product Launches, Patent Expiration to Drive Erythropoietin Drugs Market 

Darbepoetin-alfa has been developed by Amgen, Inc. as a new erythropotine drug marketed under the Aranesp brand name. This medicinal product is patented in the United States and expires in 2024. Darbepoetin-alfa is expected to be positive for its economy, improved efficiency and long half-life, in the future. This is a viable way to treat anemia caused by renal disease at the end of the stage. Research on new therapeutic fields for the application of darbepoetin-alfa is under way, which is expected to serve the global erythropoietin drugs market with substantial growth potential. 

This review is based on TMR’s report titled, “Erythropoietin Drugs Market (Drug Class – Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa; Drug Type – Biologics and Biosimilar; Drug Application – Cancer, Renal Disease, Hematology, Neurology, and Surgery and Wound Healing; Distribution Channel – Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 – 2025..” 

Get an Idea about the Offerings of Our Market Research Report from this Brochure : http://www.prnewswire.com/news-releases/despite-several-factors-supporting-osteoporosis-drugs-market-patent-expiration-of-blockbuster-drugs-to-hamper-markets-progress-tmr-301019711.html

Global Erythropoietin Drugs Market is segmented as:

Drug Class

  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa 

Drug Type

  • Biologics
  • Biosimilar 

Drug Application

  • Cancer
  • Renal Disease
  • Hematology
  • Neurology
  • Surgery and Wound Healing 

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy 

Geography

  • North AmericaU.S.
  • Canada
  • EuropeU.K.
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
  • Asia Pacific (APAC)China
  • India
  • Japan
  • Australia and New Zealand
  • Rest of APAC
  • Latin America (LATAM)Brazil
  • Mexico
  • Rest of LATAM
  • Middle East and Africa (MEA)GCC Countries
  • Israel
  • South Africa
  • Rest of MEA 

Rheumatology Therapeutics Market Latest Update Revenue by Applications, Types and Region 2017 to 2025 Research Report

The global rheumatology therapeutics market is highly competitive and consolidated due to presence of strong players, finds Transparency Market Research (TMR). Some of the key players operating in the global rheumatology therapeutics market are AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., and Merck & Co., Inc. are accounts for the leading share in the global rheumatology therapeutics market.

TMR anticipated the global revenue of the rheumatology therapeutics market was registered in 2016 US$41.88 bn and expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025 and expected to attain value of a US$ 52.96 bn by the end of 2025. On the basis of drug class, the segment biologic DMARDs has registered at the revenue of US$35.83 bn in 2016 is expected to rise at a 2.6% CAGR with this growth rate in a revenue of US$45.06 bn by 2025. This growth is attributable to high usage of Azathioprine, cyclosporine, cyclophosphamide, and methotrexate. On the basis of region, North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population.

Global Rheumatology Therapeutics

Rising Prevalence of Rheumatology Diseases to Boost Growth

Rheumatology diseases generally effects on the supporting and connecting structures and bones of the body such as joints, muscles, ligaments, tendons and some of the organs of body. It is characterized by effects on spine and inflammation of joints occurred in some of the symptoms of rheumatology disease. Early diagnosis and treatment on symptoms of rheumatology disease. Physicians generally prescribe disease-modifying anti-rheumatic drugs (DMARD’s) for treatment of rheumatologic disease. Rising prevalence of rheumatology diseases are boosting requirement of its treatments which is fuelling growth of the global rheumatology therapeutics market.  

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1494  

Additionally, technological advancements in pharmaceutical field coupled with increasing investments in healthcare industry for research and development activities. Rising trend for fitness globally which is expected to support the growth of rheumatology therapeutics market. Increasing expenditure on healthcare from mid-earing population is driving growth of the global rheumatology therapeutics market.                      

Availability of Alternatives for Rheumatology Therapeutics to Hamper Growth

However, launch of biosimilars is key factors hampering growth of the rheumatology therapeutics market. Rising demand for biosimilar products are crimping growth of the rheumatology therapeutics market. Additionally, patent expiry of well-known drugs used in the treatment of rheumatology diseases is hampering growth of the rheumatology therapeutics market. Nevertheless, increasing launches of novel biologics drugs and rising penetration of generic drugs are expected to drive growth of the market. Increasing approvals for new biologics such as Xeljanz are anticipated to account for high penetration which is likely to create opportunities in the global rheumatology therapeutics market.

This information is comprised in the new report by TMR, titled “Rheumatology Therapeutics Market (Drug Class – Disease Modifying Anti-rheumatic Drugs (DMARD’s), Nonsteroidal Anti-inflammatory Drugs (NSAID’s), Corticosteroids, and Uric Acid Drugs; Disease Indication – Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis; Distribution Channel – Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025.”

Get an Idea about the Offerings of Our Market Research Report from this Brochure : http://www.prnewswire.com/news-releases/increasing-number-of-accidents-and-injuries-to-drive-adoption-of-wound-closure-strips-market-valuation-to-rise-up-to-us446-3-mn-by-2027-end-finds-tmr-301019647.html

The global rheumatology therapeutics market has been segmented as presented:

By Drug Class:

  • Disease Modifying Anti-rheumatic Drugs (DMARD’s)
  • Nonsteroidal Anti-inflammatory Drugs (NSAID’s)
  • Corticosteroids
  • Uric Acid Drugs

By Disease Indication:

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Gout
  • Psoriatic Arthritis
  • Ankylosing Spondylitis

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North AmericaU.S.
  • Canada
  • EuropeU.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia PacificChina
  • Japan
  • Australia
  • India
  • Rest of Asia Pacific
  • Latin AmericaBrazil
  • Mexico
  • Rest of Latin America
  • Middle East & AfricaSouth Africa
  • Saudi Arabia
  • Rest of Middle East & Africa

Us Substance Abuse Treatment Market News Research Report 2024

A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their astute marketing strategies have helped to enhance their market shares majorly.

Our report, which valued the U.S. market for substance abuse treatment at US$4.42 bn in 2015, estimates it to become worth US$12.43 bn by 2024-end by rising at an impressive 12.40% CAGR between 2016 and 2024.

us substance abuse treatment market

The most prevalent substance abuse in the U.S. are those pertaining to tobacco or nicotine addiction, alcohol dependence, and opioid addiction. Among them, the tobacco or nicotine addiction leads owing to around 15.0% of people in the nation being addicted to smoking. When it comes to end users, the outpatient treatment centers are responsible for driving most of the demand mainly because their rising popularity. In the years ahead too, the segment will drive most of the demand in the market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=21773

Alarming Rise in Cases of Substance Abuse Drives Market

At the forefront of driving the market for substance abuse treatment in the U.S. is the spike in number of alcohol, opioid, and nicotine or tobacco addicts. “The federal government along with the local authorities in the nation have devised myriad early intervention and therapeutic strategies to bring the situation under control. This is expected to bode well for the market for substance abuse treatment in the near term,” states the lead analyst of TMR.

In addition, the U.S. market for substance abuse is also expected to gain from the leading companies’ efforts to enhance their customer base by generating awareness through campaigns about the harmful effects of drug abuse and the necessity of timely treatment. In order to do so, the companies are seen banking upon every medium including print, television, and online.

Strict Approval Process for New Therapies Offsets Market Growth to an Extent

On the flipside, not too many therapies for mental illness resulting from substance addiction and stringent rules pertaining to approval of therapies is dampening market growth to an extent.

The most widely sold drugs in the market for substance abuse treatment market are disulfiram, naltrexone, and acamprosate. Among them, acamprosate will likely see maximum share in the near future. Non-nicotine medications and nicotine replacement treatment have now emerged as the most effective treatments for nicotine and tobacco addiction.

This review is based on the findings of a TMR report, titled, “Substance Abuse Treatment Market (Abuse Type – Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction; Treatment Type – Alcohol Addiction Treatment (Disulfiram, Acamprosate, and Naltrexone), Tobacco/Nicotine Addiction Treatment (Nicotine Replacement Treatment and Non-nicotine Medication), Drug Abuse Treatment (Methadone, Buprenorphine, and Naltrexone); End User – Outpatient Treatment Centers, Residential Treatment Centers, and Inpatient Treatment Centers) – U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016–2024.”

Get an Idea about the Offerings of Our Market Research Report from this Brochure : http://www.prnewswire.com/news-releases/thrust-on-pharmaceutical-sector-to-develop-novel-drugs-for-clinical-conditions-propels-pharmaceutical-excipients-market-transparency-market-research-301017102.html

The report segments the U.S. Substance Abuse Treatment Market into the following:

The U.S. Substance Abuse Treatment Market, by Abuse Type

  • Alcohol Dependence
  • Tobacco/Nicotine Addiction
  • Opioid Addiction 

The U.S. Substance Abuse Treatment Market, by Treatment

  • Alcohol Addiction TreatmentDisulfiram
  • Acamprosate
  • Naltrexone
  • Tobacco/Nicotine Addiction TreatmentNicotine Replacement TreatmentNicotine Patch
  • Nicotine Gum
  • Nicotine Lozenge
  • Nicotine Spray
  • Nicotine Inhaler
  • Non-Nicotine MedicationBupropion
  • Varenicline
  • Drug Abuse TreatmentMethadone
  • Buprenorphine
  • Naltrexone 

The U.S. Substance Abuse Treatment Market, by End User

  • Outpatient Treatment Centers
  • Residential Treatment Centers
  • Inpatient Treatment Centers 

Monoclonal Antibody Therapeutics Market Companies Overview 2016 – 2024

In the global monoclonal antibody therapeutics market, keen companies are seen partnering with both their local and international counterparts to take advantage of synergies. It enables them to reduce the cost of production, funnel greater amounts into research and development, and gain access to better human resources. Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Merck & Co., Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., and AbbVie Inc. are to name a few prominent participants in the global market for monoclonal antibody therapeutics

A recent research study by Transparency Market Research projects the market for monoclonal antibody therapeutics to attain a value of US$245.8 bn by the end of the forecast period in 2024 by rising at a solid double digit 12.6% CAGR from 2016 to 2024. The estimated valuation of the market as per our report was US$86.7 bn at the start of the forecast period in 2015.

Monoclonal antibody therapeutics mostly find application in treating autoimmune diseases. This is because of the rising awareness about such diseases and their treatments, better accessibility to healthcare, and the growing applications of monoclonal antibody therapeutics on account of major thrust on their research and development. Going forward too, the rising cases of autoimmune diseases expected to generate maximum opportunities in the market. From a geographical standpoint, Europe and North America together accounted for a share of 62.7% in the global market for monoclonal antibodies therapeutics in 2015. Their market has been stoked by the rising number of elderly, solid reimbursement policies and affordable healthcare, and a strong knowledge about various diseases.

monoclonal antibody therapeutics market

Surging Cancer Cases Underpin Demand in Market

Monoclonal antibody therapeutics is essentially a biological therapy that finds usage in treating different kinds of chronic conditions. Rheumatoid arthritis, cancer, Crohn’s diseases, osteoporosis, systemic lupus erythematous, and psoriasis, among others, can be treated leveraging the therapeutics. Monoclonal antibodies target just the affected areas to annihilate the diseased cells, thus helping the immune system to rebound. The surging cancer cases worldwide is a major driver of the monoclonal antibody therapeutics market. As per the WHO, cancer cases are expected to rise by 70.0% in the next couple of years and this will spell immense opportunities for the market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18209

Apart from rising cases of cancer, investments into research and development of new antibodies, especially in the U.S. and Europe, along with speedy approval and commercialization of these drugs will also contribute to the surging revenue in the market. Our report finds that around five to six monoclonal antibodies receive a nod from regulatory bodies in these regions every year for launch in market.

Biosimilars, Used in Treating Similar Medical Conditions, Slow Down Demand for Monoclonal Antibodies

Despite the bright potential of the market, it is expected to be hobbled by the growing manufacture of biosimilars, which also find application in treating different autoimmune diseases and chronic conditions. In addition, expiry of patents for many monoclonal antibodies coupled with expensive and complex manufacturing process is hampering market growth. All such factors are serving to drive up prices of the final product thereby dampening sales.

This review is based on the findings of a TMR report, titled, “Monoclonal Antibody Therapeutics Market (Application – Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Ophthalmological Diseases, and Others; Source – Human, Humanized, Chimeric, and Others; End User – Hospitals, Private Clinic and Research Institute) – Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016–2024.”

Get an Idea about the Offerings of Our Market Research Report from this Brochure : https://www.prnewswire.com/news-releases/rising-complications-due-to-diabetes-is-pushing-adoption-of-diabetic-ulcers-treatment-market-valuation-will-rise-up-to-us13-6-bn-by-2026-end-finds-tmr-report-301016214.html

The report segments the Global Monoclonal Antibody Therapeutics Market into the following:

Global Monoclonal Antibody Therapeutics Market, by Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others

Global Monoclonal Antibody Therapeutics Market, by Source

  • Human
  • Humanized
  • Chimeric
  • Others

Global Monoclonal Antibody Therapeutics Market, by End Users

  • Hospitals
  • Private Clinics
  • Research Institute

Global Monoclonal Antibody Therapeutics Market, by Geography

  • North AmericaU.S.
  • Canada
  • Latin AmericaBrazil
  • Mexico
  • Rest of Latin America
  • EuropeU.K.
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia PacificIndia
  • Japan
  • China
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • Middle East and AfricaSouth Africa
  • Saudi Arabia
  • E.
  • Rest of MEA

Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, Advancement and Precise Outlook – 2023

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=504

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

This analysis of the global non-small cell lung cancer market is based on a recent market research report by Transparency Market Research, titled “Non-Small Cell Lung Cancer Therapeutics Market (Pipeline – Early Stage (Phase I and II) and Late Stage (Phase III); Drug Class – Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Get an Idea about the Offerings of Our Market Research Report from this Brochure : https://www.prnewswire.co.uk/news-releases/analytical-standards-market-to-clock-6-cagr-during-2019-2027-environmental-regulations-provide-steady-impetus-transparency-market-research-825939702.html

For the study, the marke has been segmented as follows:

  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)Overview
  • Angiogenesis InhibitorAvastin (bevacizumab)
  • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor BlockerTarceva (erlotinib)
  • Gilotrif (afatinib)
  • Iressa (gefitinib)
  • Kinase InhibitorXalkori (crizotinib)
  • Zykadia (ceritinib)
  • Microtubule StabilizerAbraxane (paclitaxel protein bound)
  • Docetaxel
  • Folate AntimetabolitesAlimta (pemetrexed)
  • PD-1/ PD-L1 InhibitorOpdivo (nivolumab)
  • Keytruda (pembrolizumab)
  • Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics MarketOverview
  • Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)Avelumab – Pfizer, Inc.
  • MPDL3280A – Roche
  • MEDI4736 – AstraZeneca
  • Abemaciclib – Eli Lilly and Company
  • Others
  • Early Stage (Phase I and II) (Qualitative Analysis – Tabular representation)
  • Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)Overview
  • North AmericaU.S.
  • Canada
  • EuropeU.K.
  • Germany
  • Rest of Europe
  • Asia PacificJapan
  • China
  • Rest of Asia Pacific
  • Rest of the World

Systemic Lupus Erythematosus Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 – 2027

Transparency Market Research (TMR) has published a new report on the systemic lupus erythematosus treatment market for the forecast period of 2019–2027. According to the report, the global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018, and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Systemic Lupus Erythematosus Treatment Market: Overview

  • Growth of the global systemic lupus erythematosus treatment market can be attributed to rise in the incidence of systemic lupus erythematosus, and promising drug pipeline and approvals.
  • North America dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, and the presence of major market players are expected to drive the market in North America.
  • Asia Pacific is expected to be a highly lucrative market for systemic lupus erythematosus treatment, expanding at a high CAGR during the forecast period.

Immunosuppressive Drugs to Dominate Market

  • Based on drug, the global systemic lupus erythematosus treatment market has been divided into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, immunosuppressive drugs, and others (biologics, B-cell modulators, etc.).
  • The immunosuppressive drugs segment dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is likely to continue during the forecast period.
  • Immunosuppressive drugs such as azathioprine, cyclophosphamide, and methotrexate help control inflammation and the overactive immune system in the treatment of SLE. Furthermore, increase in the popularity of methotrexate as a treatment option is likely to boost the growth of this segment.
  • The immunosuppressive drugs segment can be further segmented into azathioprine, cyclophosphamide, methotrexate, and others. In terms of immunosuppressive drugs, the azathioprine sub-segment is anticipated to dominate the market.

Oral Mode of Delivery to be Popular

  • In terms of mode of delivery, the global systemic lupus erythematosus treatment market can be divided into intravenous, subcutaneous, and oral.
  • The oral segment dominated the global systemic lupus erythematosus treatment market, due to an increase in the preference for self-administration of drugs such as immunosuppressive drugs, antimalarial drugs, and corticosteroids. This, in turn, is projected to drive the segment during the forecast period.
  • Furthermore, major market players are focusing on the launching of new products in the tablet and capsule form. This is likely to boost the growth of the segment during the forecast period.
  • The intravenous segment is expected to be a highly lucrative segment of the market during the forecast period. The intravenous route helps in the immediate delivery of drug, and since the delivery is into a vein, the drug starts working immediately. Moreover, drug degradation is less as compared to the oral route of administration.

Retail Pharmacies Accounted for Major Share of Market

  • Based on distribution channel, the global systemic lupus erythematosus treatment market has been segmented into hospital pharmacies, retail pharmacies, and online sales.
  • The retail pharmacies segment dominated the global systemic lupus erythematosus treatment market in terms of revenue in 2018, and the trend is projected to continue during the forecast period. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, such as NSAIDS, antimalarial drugs, and corticosteroids, as OTC drugs in retail stores, are likely to propel this segment during the forecast period.
  • Hospital pharmacies is expected to be the second-most lucrative segment of the global systemic lupus erythematosus treatment market during the forecast period. The segment is expected to expand at a significant CAGR from 2019 to 2027, due to an increase in the demand for recently launched new products for systemic lupus erythematosus treatment.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73932

North America to Dominate Global Market

  • In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global systemic lupus erythematosus treatment market in 2018, followed by Europe.
  • North America accounted for a major share of the global systemic lupus erythematosus treatment market in 2018, owing to an increase in the use of systemic lupus erythematosus treatment products, especially for various symptoms of the disease. Additionally, the launch of new products by major pharmaceutical manufacturers fuels the market in this region.
  • The systemic lupus erythematosus treatment market in Asia Pacific is likely to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in the prevalence of systemic lupus erythematosus, improving healthcare infrastructure in terms of better facilities, and rise in the demand for advanced products. According to a latest study, the prevalence was in the range of 4.3 to 45.3/100,000 person per year.

Systemic Lupus Erythematosus Treatment Market: Competitive Landscape

  • The global systemic lupus erythematosus treatment market is fragmented in terms of number of players.
  • Key players operating in the global market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC, and Aurinia Pharmaceuticals, Inc.

Get an Idea about the Offerings of Our Market Research Report from this Brochure : https://www.prnewswire.com/news-releases/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-reach-us-26-2-bn-in-2027-drug-makers-focus-on-combination-therapies-transparency-market-research-301011476.html

Systemic Lupus Erythematosus Treatment Market: Segmentation

The global systemic lupus erythematosus treatment market has been segmented as:

  • Systemic Lupus Erythematosus Treatment Market by DrugAntimalarial DrugsChloroquine
  • Hydrochloroquine
  • Non-steroidal Anti-inflammatory Drugs (NSAIDS)Ibuprofen
  • Naproxen
  • Others
  • CorticosteroidsPrednisone
  • Hydrocortisone
  • Dexamethasone
  • Others
  • Immunosuppressive DrugsAzathioprine
  • Cyclophosphamide
  • Methotrexate
  • Others
  • Others (Biologics, B-cell Modulators, etc.)
  • Systemic Lupus Erythematosus Treatment Market by Mode of DeliveryIntravenous
  • Subcutaneous
  • Oral
  • Systemic Lupus Erythematosus Treatment Market by Distribution ChannelHospital Pharmacies
  • Retail Pharmacies
  • Online Sales
  • Systemic Lupus Erythematosus Treatment Market by RegionNorth AmericaU.S.
  • Canada
  • EuropeGermany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia PacificChina
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin AmericaBrazil
  • Mexico
  • Rest of Latin America
  • Middle East & AfricaGCC Countries
  • South Africa
  • Rest of Middle East & Africa